BioWorld

Feb. 7, 2011

The Dark Side of Demand: Scaling Up Biologics

Increased demand for a drug is a welcome outcome of gaining regulatory approval and successful marketing. But scaling up production of biologics isn't easy. Read More

Money Raised Year to Date

Antitrust Probe for Alexion? History Shows No Big Deal

Obesity Drug Strike-Out May Shift Focus Back to GLP-1s

Week in Review

Word on the Street

U.S. Public Offering Performance By Underwriter: Jan. 1 - Dec. 31, 2010

Underwriters' Performance on IPOs: Jan. 1 - Dec. 31, 2010

Lead Underwriter Performance on All U.S. Offerings: Jan. 1 - Dec. 31, 2010

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...